Integrated findings showed system-level factors overriding physician knowledge and intent.<h4>Conclusion</h4>Barriers to SGLT2 inhibitor use for HF in Jordan are predominantly systemic. This evidence concerns the gene SLC5A2 and hydrops fetalis.